Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Reuben M. Valenzuela"'
Autor:
Edward C. Rainville, Jinma Ren, Carl V. Asche, Tommaso Raimondi, Marisa Ayari Ascencio, Reuben M. Valenzuela
Publikováno v:
Clinical Therapeutics. 41:1477-1485
Purpose Ipratropium and salmeterol were found to stimulate oligodendrocyte differentiation in a high-throughput drug screening assay; thus, they may play a role in the risk reduction of multiple sclerosis (MS). So far, they have not been examined in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1973594071646264062bb195745ff51f
https://doi.org/10.1016/j.clinthera.2019.04.039
https://doi.org/10.1016/j.clinthera.2019.04.039
Publikováno v:
Current Medical Research and Opinion. 33:1451-1456
The associations between allergies, antibiotics use, and multiple sclerosis (MS) remain controversial and their mediating or moderating effects have not yet been examined. We aimed to assess the direct and indirect influences of allergies and antibio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3783c8d6de9d5467ea982cf760d59c6
https://doi.org/10.1080/03007995.2017.1325575
https://doi.org/10.1080/03007995.2017.1325575
Autor:
Cheryl A. Palmer, Judith E. A. Warner, Reuben M. Valenzuela, Anne G. Osborn, Gregory D. Kramer, Kathleen B. Digre, Julia M. Byrd
Publikováno v:
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 36(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e71aa310bbfdbd26a8f63382696419
https://pubmed.ncbi.nlm.nih.gov/27391943
https://pubmed.ncbi.nlm.nih.gov/27391943
Autor:
Kouichi Ito, John E. Mindur, Sudhir K. Yadav, Reuben M. Valenzuela, Sridhar Boppana, Suhayl Dhib-Jalbut
Publikováno v:
Journal of neuroimmunology. 304
Glatiramer acetate (GA) is an FDA-approved efficacious drug for the treatment of relapsing-remitting multiple sclerosis (RRMS). However, this treatment is not effective for all RRMS patients. Therefore, it is important to identify reliable biomarkers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0886d5849ac07a252863173abbd428e2
https://pubmed.ncbi.nlm.nih.gov/27449853
https://pubmed.ncbi.nlm.nih.gov/27449853
Autor:
Christopher T. Bever, David Trisler, Karna T. Sura, Ishwar S. Singh, Tapas K. Makar, David Ford, Aditi Gupta, Reuben M. Valenzuela, Shireen Sultana, James E. Goolsby, Suhayl Dhib-Jalbut, Shailesh Balasubramanian, Niraj Patel
Publikováno v:
Journal of Neuroimmunology. 196:67-81
Interferon-beta (IFN-beta), an approved treatment of multiple sclerosis (MS), produces only partial clinical responses. IFN-beta therapy has been limited by its short serum half-life and limited ability to cross the blood brain barrier. We have devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c7d224e5770c5ac97bf09909332f6d2
https://doi.org/10.1016/j.jneuroim.2008.02.014
https://doi.org/10.1016/j.jneuroim.2008.02.014
Autor:
Michael Kaufman, Steve Buyske, Kouichi Ito, Reuben M. Valenzuela, Mary Ann Picone, Suhayl Dhib-Jalbut
Publikováno v:
Multiple sclerosis and related disorders. 2(4)
Clinical response to immunomodulatory therapies in multiple sclerosis (MS) is variable among patients. Currently, there are no validated biomarkers of clinical response to any of the approved treatments for MS. The objective of this study was to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2dca43e148ba8208716c8aa84196723
https://pubmed.ncbi.nlm.nih.gov/25877844
https://pubmed.ncbi.nlm.nih.gov/25877844
Autor:
Kouichi Ito, Reuben M. Valenzuela, Mark Rametta, Suhayl Dhib-Jalbut, Sumandeep Sumandeep, Payal Patel
Publikováno v:
Journal of neuroimmunology. 254(1-2)
We measured immune markers in subjects with multiple sclerosis (MS) treated with IFNβ-1b for 12 months. IL-17 levels were significantly higher at Month 6 ( p = 0.036) in relapsing subjects while BDNF levels were significantly higher at Month 3 ( p =
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43ebb60f346eb18b3f4e73a0b88bbd2b
https://pubmed.ncbi.nlm.nih.gov/22999187
https://pubmed.ncbi.nlm.nih.gov/22999187
Autor:
Areen T Said, Kenneth P. Johnson, K Costello, Man Chen, Reuben M. Valenzuela, Suhayl Dhib-Jalbut
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England). 13(6)
Objective To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-γ and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS). Background GA therapy involves the induction of anti-inflammatory cytok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cafa36be5fa1f34274dcc327211d082d
https://pubmed.ncbi.nlm.nih.gov/17613604
https://pubmed.ncbi.nlm.nih.gov/17613604